Intelligence Feed event · Policy · 2026-10-19

    Oculis Completes PREDICT-1 Registrational Randomization in Dry Eye Candidate

    Question

    Oculis Completes PREDICT-1 Registrational Randomization in Dry Eye Candidate

    Direct answer

    Oculis Holding announced the completion of patient randomization for its PREDICT-1 registrational clinical trial evaluating Licaminlimab. The trial enrolled 176 subjects presenting with TNFR1-mediated dry eye disease, achieving targeted precision stratification. Approximately two-thirds of the study cohort carry the specific TNFR1 genetic variant previously demonstrated to correlate with improved clinical response. Finalizing randomization establishes the timeline for primary registrational readouts in ocular precision medicine.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-19
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Oculis Completes PREDICT-1 Registrational Randomization in Dry Eye Candidate”, revision 1, evidence through 2026-10-19. https://marketontology.com/market-events/2026-10-19/oculis-completes-predict-1-registrational-randomization-in-dry-eye-candidate-54ec81

    POLICY
    Oculis Completes PREDICT-1 Registrational Randomization in Dry Eye Candidate
    Oculis Holding announced the completion of patient randomization for its PREDICT-1 registrational clinical trial evaluating Licaminlimab. The trial enrolled 176 subjects presenting with TNFR1-mediated dry eye disease, achieving targeted precision stratification. Approximately two-thirds of the study cohort carry the specific TNFR1 genetic variant previously demonstrated to correlate with improved clinical response. Finalizing randomization establishes the timeline for primary registrational readouts in ocular precision medicine.
    OCS
    Impact
    57
    OCT 19
    SIG
    OCS
    Oculis Completes PREDICT-1 Registrational Randomization in Dry Eye Candidate
    Oculis Holding announced the completion of patient randomization for its PREDICT-1 registrational clinical trial evaluating Licaminlimab. The trial enrolled 176 subjects presenting with TNFR1-mediated dry eye disease, achieving targeted precision stratification. Approximately two-thirds of the study cohort carry the specific TNFR1 genetic variant previously demonstrated to correlate with improved clinical response. Finalizing randomization establishes the timeline for primary registrational readouts in ocular precision medicine.
    → Full enrollment in registrational cohorts locks in the clinical milestone timeline, driving biotech asset repricing for OCS ahead of primary endpoint data.
    Impact
    Oculis Holding announced the completion of patient randomization for its PREDICT-1 registrational clinical trial evaluating Licaminlimab. The trial enrolled 176 subjects presenting with TNFR1-mediated dry eye disease, achieving targeted precision stratification. Approximately two-thirds of the study cohort carry the specific TNFR1 genetic variant previously demonstrated to correlate with improved clinical response. Finalizing randomization establishes the timeline for primary registrational readouts in ocular precision medicine.
    Affected
    OCS
    Transmission
    Full enrollment in registrational cohorts locks in the clinical milestone timeline, driving biotech asset repricing for OCS ahead of primary endpoint data.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    OCSclinical milestone derisking into registrational readoutUp1-3mCompleted randomization of 176 patients in PREDICT-1 trial

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month